WASHINGTON, May 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2023, to be held in Chicago, IL and online from May 6-9, 2023.
The following will be presented:
May 7, 2023
Presentation Title: "THE ROLE OF TENASCIN-X IN IDIOPATHIC GASTROPARESIS: WGS ANALYSIS"
Poster Number: Su1618
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT
Presentation Title: "POOLED EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS STUDY VP-VLY-686-3301 AND VP-VLY-686-2301"
Poster Number: Su1632
Presenter: Dr. Jesse L. Carlin, Clinical Project Lead
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT
Presentation Title: "EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301"
Poster Number: Su1633
Presenter: Dr. Jesse L. Carlin, Clinical Project Lead
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT
Presentation Title: "A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS"
Poster Number: Su1634
Presenter: Dr. Jesse L. Carlin, Clinical Project Lead
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time: 12:30 PM to 1:30 PM CDT
For more information on DDW 2023, please refer to https://ddw.org/.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
This email address is being protected from spambots. You need JavaScript enabled to view it.
Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.33 |
| Daily Volume: | 0 |
| Market Cap: | US$252.480M |
February 24, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
